logo-loader
viewMedlab Clinical Ltd

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.
 
Hall says there has been a shortfall in the standard of quality healthcare today and Medlab is looking to provide better new health solutions.
 
The company is doing extensive work exploring the role gut health plays in chronic illnesses and developing quality nutraceuticals, popular treatments that contributed towards Medlab's revenue milestones last month.

Quick facts: Medlab Clinical Ltd

Price: 0.385 AUD

ASX:MDC
Market: ASX
Market Cap: $82.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical chief updates on progress with NanaBis and NRG Biotic

Medlab Clinical Ltd (ASX:MDC) managing director & CEO Sean Hall visits Proactive's Sydney studio following participation at the Australian Pharmacy Professional Conference & Trade Exhibition (APP2019). Hall updates on the progress of clinical trials for NRGBiotic™, a nutraceutical...

on 12/3/19

2 min read